PSMA PET/CT Beyond the Images: The Imager’s and Clinician’s Perspective
PSMA PET/CT Beyond the Images: The Imager’s and Clinician’s Perspective
EDITORIAL COMMITTEE: Bobby Shayegan, Katherine Zukotynski, Frédéric Pouliot, Stefano Fanti
By the end of this program, participants will be able to:
- Describe the several PSMA-targeting tracers and PET/CT technology
- Describe the accuracy of PSMA-PET/CT for staging and re-staging prostate cancer based on best prospective studies
- Understand the basis of PSMA radioligand therapy and the trials in metastatic prostate cancer
This program has received financial support from The ICPO Foundation, Oncidium Foundation, and Advanced Accelerator Applications: A Novartis Company in the form of an educational grant